Intrinsic Medicine and Phoenix Biotech Acquisition Corp. Announce Merger Agreement to Create Public Company Leveraging Human Milk Biology to Treat Gut-Brain Axis Disorders.Read more including important disclaimers
New Medicines for Gut-Brain Axis Disorders
Bioactive, synthetically produced human milk oligosaccharides (HMOs) with the potential to be transformative new medicines by modulating the gut microbiome and immune system.Pipeline
Company Overview & Vision
We are a therapeutics company leveraging human milk biology to create new medicines to transform gut-brain axis (GBA) disorders with large populations underserved by current treatment options. Our initial drug candidates are based on bioactive oligosaccharides naturally produced in human milk, or HMOs, which directly modulate the immune system and other human cells, as well as the gut microbiome.
We believe our synthetic biology-manufactured human milk oligosaccharide, or HMO, drug candidates have the potential to affect multiple pathways implicated in GBA disorders and certain inflammatory disorders, while reproducing the favorable safety and tolerability profile observed of HMOs. We are prioritizing the development of our drug candidates for disorders where available treatment options are inadequately serving people living with GBA disorders due to safety or tolerability issues and where we have the potential to redefine the standard of care.
By developing new drugs from some of the safest bioactive compounds on the planet.
Standard of care in diseases where current treatments have significant limitations.
What a truly safe, effective, and financially accessible drug means to the healthcare system.